Strategies & Technologies Driving Drug Discovery to Market
The Lead
Mass Spec Maturing in the Age of Proteomics
June 11, 2013 11:45 am | by Neil Canavan, Contributing Editor | Articles | Comments
Biomarkers are the order of the day—an endogenous signal flare that’s fired, perhaps even before actual disease onset, warning of impending illness. The problem for the clinician, and way before that, the researcher at the bench is how do you detect that tiny, diagnostically incandescent signal.
Pay-to-Delay Can Be Challenged
June 17, 2013 11:00 am | by Jesse J. Holland | News | Comments
The Supreme Court ruled that deals between pharmaceutical corporations and their generic drug...
J&J Acquiring Aragon for $650M
June 17, 2013 10:43 am | News | Comments
Johnson & Johnson said that it has agreed to buy Aragon Pharmaceuticals Inc. for at least $...
Court to Hear Drug Liability Arguments
June 16, 2013 11:13 am | News | Comments
The Alabama State Supreme Court is reconsidering a decision allowing makers of name brand drugs...
Clinical Possibilities of Metal–Peptide Complexes
June 17, 2013 5:10 pm | by Archana Gangakhedkar; American Peptide Company Inc., Sunnyvale, Calif. | Articles | CommentsMetal-peptide complexes play an important role in understanding the mechanisms behind complex diseases at the molecular level. Peptides are good chelators for metal ions and can form important tools in the drug and medical device industries.
Simultaneous, Formalin-Free Preservation of Tissue Biomarkers and Morphology for Biomarker Discovery and Biobanking
June 17, 2013 11:47 am | Webinars | CommentsIn this webinar, PreAnalytix will introduce a new technology, the PAXgene Tissue System, which preserves tissue morphology, DNA, RNA, miRNA, proteins, and phosphoproteins in the same sample without cross-linking of biomolecules or damage to the tissue architecture or histomorphology.
Lilly Developing Diabetes Drug
June 17, 2013 9:16 am | News | CommentsEli Lilly and Co. will pay Transition Therapeutics Inc. $7 million and take over the development of a potential diabetes treatment heading into mid-stage clinical testing. Transition could also receive up to $240 million in additional payments, plus royalties if the treatment is eventually approved and sold.
Mining for Adverse Events
June 15, 2013 12:17 pm | by Christina Smith, News Editor | Articles | CommentsAs electronic medical records continue to debut in hospitals across the country, researchers are exploring ways to optimize the data hidden in clinical notes that could benefit the pharmaceutical community—by finding early signs of potentially harmful drug side effects.
Abbott May Buy Back $3B in Stock
June 14, 2013 1:02 pm | News | CommentsAbbott Laboratories plans to buy back up to $3 billion of its common stock, replacing a finished $5 billion program that began before the health care company separated from its drug business. Abbott makes generic drugs, medical implants, and nutritional formula.
Supreme Court: Genes Can't Be Patented
June 14, 2013 10:56 am | by Linda A. Johnson | News | CommentsThe Supreme Court handed Myriad Genetics Inc. a partial victory in a battle over the validity of patents underlying its test for genes linked to high risk of breast and ovarian cancer. The ruling likely will eventually benefit rivals, as well as doctors and patients wanting to determine the best course of treatment.
Thyroxin Could Target Autism and FAD
June 14, 2013 10:40 am | News | CommentsIn a surprising new finding, a study has found a common molecular vulnerability in autism and fetal alcohol spectrum disorder. Both disorders have symptoms of social impairment and originate during brain development in utero. This damage may be reverseable, however.
Researchers Program Blood Stem Cells
June 14, 2013 10:29 am | News | CommentsBy transferring four genes into mouse fibroblast cells, researchers have produced cells that resemble hematopoietic stem cells, which produce millions of new blood cells in the human body every day. These findings provide a platform for development of cell-replacement therapy.
Lilly Stops Alzheimer's Study
June 13, 2013 5:41 pm | News | CommentsEli Lilly and Co. has stopped a mid-stage clinical trial of an experimental Alzheimer's disease drug because of potential side effects on patients' livers. The company stopped testing LY2886721 because of abnormal results in liver biochemical tests.
CILS Labels Aid Cryogenic Storage
June 13, 2013 11:47 am | Product Releases | CommentsDeveloped for liquid nitrogen freezing and long-term cryogenic freezer storage, laboratory labeling specialists CILS have launched a computer printable durable label for ultra low temperatures, providing immediate permanent adhesion to all cyrovials, tubes, and liquid straws stored down to -196ºC.
Nanotech Improving Tumor Targeting
June 13, 2013 11:31 am | News | CommentsNanotechnology opens up a portal into living tissue that allows scientists to watch cancers spreading, and to determine which parts of a tumor should be targeted. Clinicians can then see where they need to improve on drug delivery to improve clinical outcome.
Trebananib Meets Primary Study Goal
June 13, 2013 10:20 am | News | CommentsAmgen announced that a Phase 3 clinical trial evaluating trebananib plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival. Investigators observed a 34% reduction in the risk of disease progression or death.
Markers Predict Breast Cancer Therapy Response
June 13, 2013 10:00 am | News | CommentsGenetic variations in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene. Women who have the favorable variations of these two SNPs are more likely to respond to prevention therapy.
GSK Finds No Evidence of Bribery
June 13, 2013 2:58 am | News | CommentsDrug manufacturer GlaxoSmithKline said it has investigated an accusation that its salespeople in China bribed doctors and found no evidence of wrongdoing. The company said it conducted a four-month investigation after receiving complaints from an anonymous source.
MPI, inviCRO, 3D Imaging Collaborate
June 12, 2013 10:47 am | News | CommentsMPI Research has announced a strategic partnership with inviCRO and 3D Imaging to unite world-class molecular imaging, radiochemistry, and informatics to accelerate drug discovery and development. The new center provides developers with contiguous access to a cyclotron and vivarium facilities.
